ADIM
RCUS icon

Alpha DNA Investment Management’s Arcus Biosciences RCUS Stock Holding History

Alpha DNA Investment Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-28,690
Closed -$548K – 236
2023
Q4 		$548K Buy
28,690
+2,974
+12% +$47.5K 0.21% 97
2023
Q3 		$462K Buy
+25,716
New +$517K 0.19% 145

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Alpha DNA Investment Management's RCUS Position: Q1 2024 in Review

Alpha DNA Investment Management sold out of Arcus Biosciences (RCUS) in Q1 2024, closing a stake of 28,690 shares — an estimated $548K sold.

Alpha DNA Investment Management first reported a position in RCUS in Q3 2023 and held it in 2 quarters. The position peaked at $548K in Q4 2023. 172 funds tracked by Wall St. Rank hold RCUS as of Q1 2024.

  • Alpha DNA Investment Management reported no remaining Arcus Biosciences position as of Q1 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 28,690 Arcus Biosciences shares in Q1 2024, an estimated $548K.
  • Alpha DNA Investment Management first reported a position in Arcus Biosciences in Q3 2023 and held it in 2 quarters.
  • Alpha DNA Investment Management's Arcus Biosciences position peaked at $548K in Q4 2023.
  • 172 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2024.

Based on Alpha DNA Investment Management's 13F filing for Q1 2024, filed 15 May 2024.